MAIA Biotechnology's stock drops 28% after $30 million offering announcement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy MAIA?
Source: stocktwits
MAIA Biotechnology Inc's stock fell 28.26% as it crossed below the 5-day SMA, reflecting investor concerns following the announcement of a public offering.
The company announced a public offering of 20 million shares at $1.50 each, aiming for gross proceeds of $30 million to fund clinical trials and working capital. This move indicates the company's urgent need for funding, which has raised concerns among investors about its future prospects in the competitive biopharmaceutical sector. The offering is expected to close on March 4, 2026, subject to customary closing conditions, which may influence short-term investor decisions.
The significant drop in stock price highlights the market's reaction to the offering, as investors weigh the implications of potential dilution and the company's financial health. Despite the funding aimed at advancing its cancer immunotherapy pipeline, the market's immediate response reflects uncertainty about MAIA's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAIA
Wall Street analysts forecast MAIA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.410
Low
14.00
Averages
14.00
High
14.00
Current: 1.410
Low
14.00
Averages
14.00
High
14.00
No data
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MAIA Biotechnology Reports Progress in THIO-101 Clinical Trial for NSCLC
- Clinical Trial Launch: MAIA Biotechnology has activated the first clinical site for its THIO-101 expansion trial in the U.S., expected to provide new treatment options for approximately 50,000 patients with resistant non-small cell lung cancer annually, significantly enhancing the company's market position in cancer immunotherapy.
- Funding Support: The trial is backed by a $2.3 million grant from the National Institutes of Health (NIH), underscoring the research value and potential market impact of the project, thereby strengthening MAIA's financing capabilities in the competitive biopharmaceutical industry.
- Exceptional Efficacy Data: THIO-101 demonstrated outstanding efficacy data in 2025, with overall survival exceeding 24 months, far surpassing existing treatment standards, indicating the drug's potential to become a best-in-class option in non-small cell lung cancer treatment.
- FDA Fast Track Designation: MAIA's lead drug has received FDA Fast Track designation, which accelerates the development and review process for serious conditions, and if criteria are met, it may qualify for FDA Accelerated Approval and Priority Review, further enhancing its competitive edge in the market.
See More
MAIA Biotechnology Raises $33 Million to Advance Clinical Trials
- Funding Boosts Clinical Trials: MAIA Biotechnology has secured $33 million in funding, ensuring full financial support for its pivotal Phase 3 trial of Ateganosine (THIO) in non-small cell lung cancer (NSCLC), thereby solidifying the company's clinical ambitions in the oncology sector.
- Innovative Drug Mechanism: Ateganosine targets telomeres, damaging cancer cell DNA and activating the immune system, with earlier studies indicating rapid and durable tumor regression, potentially positioning it as the first-in-class telomere-targeting therapy for patients with limited treatment options.
- THIO-104 Trial Design: The THIO-104 trial is a global, multicenter, open-label study evaluating the efficacy of Ateganosine in combination with a checkpoint inhibitor, aiming to enroll up to 300 patients and primarily assess overall survival, making it a critical test against standard chemotherapy.
- Significant Market Potential: Lung cancer remains a leading cause of cancer deaths worldwide, and Ateganosine could provide new treatment options for patients who progress after chemotherapy and immunotherapy, enhancing survival rates and quality of life, aligning with MAIA's mission.
See More
MAIA Biotechnology Secures $33 Million for Phase 3 Trial
- Clear Funding Purpose: MAIA Biotechnology announced that the net proceeds from its $33 million public offering will fully fund its ongoing pivotal Phase 3 clinical trial for its lead investigational drug, ateganosine, targeting non-small cell lung cancer (NSCLC), demonstrating the company's strong commitment to research and development.
- Innovative Drug Mechanism: Ateganosine is designed as a dual mechanism therapy that aims to break down telomere structure and function in cancer cells while inducing immune activation, potentially providing new treatment options for NSCLC patients and enhancing the company's competitiveness in oncology.
- FDA Fast Track Designation: The U.S. Food and Drug Administration has granted Fast Track designation for ateganosine in third-line NSCLC treatment, which not only accelerates the drug's development process but also may provide the company with quicker market access opportunities.
- Positive Market Reaction: Following the public offering announcement, MAIA's stock price rose 5.0% in pre-market trading to $1.26, reflecting investor confidence in the company's future prospects and expectations for the success of its clinical trial.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
MAIA Biotechnology Reports Significant Progress in THIO-101 Trial
- Survival Milestone: In the THIO-101 trial, eight patients survived beyond two years after receiving Ateganosine followed by Cemiplimab, significantly exceeding standard survival expectations for late-stage non-small cell lung cancer patients, indicating the potential breakthrough nature of this therapy.
- Remarkable Efficacy: One third-line patient achieved 33 months of survival, far surpassing the expected 5.8 months, while four second-line patients lived beyond 30 months, well above the documented 10.5-month survival typically seen with chemotherapy or checkpoint inhibitors alone, highlighting the treatment's effectiveness.
- Trial Design Highlights: THIO-101 is a multicenter, open-label Phase 2 study primarily assessing safety and anti-tumor activity, currently expanding into Part C with plans to enroll 48 additional patients in Asia and Europe, demonstrating an acceptable safety profile in a heavily pre-treated population.
- Broad Market Potential: MAIA aims to develop Ateganosine as a second-line or later treatment for non-small cell lung cancer patients, with the global immunotherapy market projected to exceed $50 billion, positioning Ateganosine as a potential entrant with a novel mechanism and differentiated clinical profile.
See More
MAIA Biotechnology Reports Breakthrough in Lung Cancer Treatment
- Significant Survival Improvement: In the THIO-101 clinical trial, eight non-small cell lung cancer patients achieved overall survival beyond two years, with one patient in third-line therapy surviving 33 months, far exceeding the expected 5.8 months, indicating the potential breakthrough efficacy of this treatment.
- Efficacy Validation: Among 24 patients in second-line therapy, survival exceeded 30 months compared to a standard treatment survival of only 10.5 months, suggesting that this treatment regimen could redefine existing standards of care for heavily pre-treated patients.
- Clinical Trial Expansion: The THIO-101 trial is currently enrolling up to 48 participants in Asia and Europe, further validating the safety and efficacy of this therapy, which is expected to provide new treatment options for heavily pre-treated patients.
- Innovative Mechanism: Ateganosine, as the first telomere-targeting agent, demonstrates unique advantages in treating non-small cell lung cancer by inducing specific immune responses and cancer cell death, potentially paving the way for new cancer treatment strategies.
See More
MAIA Biotechnology Reports Progress in THIO-101 Clinical Trial for NSCLC
- Clinical Trial Launch: MAIA Biotechnology has activated the first clinical site for its THIO-101 expansion trial in the U.S., expected to provide new treatment options for approximately 50,000 patients with resistant non-small cell lung cancer annually, significantly enhancing the company's market position in cancer immunotherapy.
- Funding Support: The trial is backed by a $2.3 million grant from the National Institutes of Health (NIH), underscoring the research value and potential market impact of the project, thereby strengthening MAIA's financing capabilities in the competitive biopharmaceutical industry.
- Exceptional Efficacy Data: THIO-101 demonstrated outstanding efficacy data in 2025, with overall survival exceeding 24 months, far surpassing existing treatment standards, indicating the drug's potential to become a best-in-class option in non-small cell lung cancer treatment.
- FDA Fast Track Designation: MAIA's lead drug has received FDA Fast Track designation, which accelerates the development and review process for serious conditions, and if criteria are met, it may qualify for FDA Accelerated Approval and Priority Review, further enhancing its competitive edge in the market.
See More
MAIA Biotechnology Raises $33 Million to Advance Clinical Trials
- Funding Boosts Clinical Trials: MAIA Biotechnology has secured $33 million in funding, ensuring full financial support for its pivotal Phase 3 trial of Ateganosine (THIO) in non-small cell lung cancer (NSCLC), thereby solidifying the company's clinical ambitions in the oncology sector.
- Innovative Drug Mechanism: Ateganosine targets telomeres, damaging cancer cell DNA and activating the immune system, with earlier studies indicating rapid and durable tumor regression, potentially positioning it as the first-in-class telomere-targeting therapy for patients with limited treatment options.
- THIO-104 Trial Design: The THIO-104 trial is a global, multicenter, open-label study evaluating the efficacy of Ateganosine in combination with a checkpoint inhibitor, aiming to enroll up to 300 patients and primarily assess overall survival, making it a critical test against standard chemotherapy.
- Significant Market Potential: Lung cancer remains a leading cause of cancer deaths worldwide, and Ateganosine could provide new treatment options for patients who progress after chemotherapy and immunotherapy, enhancing survival rates and quality of life, aligning with MAIA's mission.
See More
MAIA Biotechnology Secures $33 Million for Phase 3 Trial
- Clear Funding Purpose: MAIA Biotechnology announced that the net proceeds from its $33 million public offering will fully fund its ongoing pivotal Phase 3 clinical trial for its lead investigational drug, ateganosine, targeting non-small cell lung cancer (NSCLC), demonstrating the company's strong commitment to research and development.
- Innovative Drug Mechanism: Ateganosine is designed as a dual mechanism therapy that aims to break down telomere structure and function in cancer cells while inducing immune activation, potentially providing new treatment options for NSCLC patients and enhancing the company's competitiveness in oncology.
- FDA Fast Track Designation: The U.S. Food and Drug Administration has granted Fast Track designation for ateganosine in third-line NSCLC treatment, which not only accelerates the drug's development process but also may provide the company with quicker market access opportunities.
- Positive Market Reaction: Following the public offering announcement, MAIA's stock price rose 5.0% in pre-market trading to $1.26, reflecting investor confidence in the company's future prospects and expectations for the success of its clinical trial.
See More
Biotech Landscape Update: Regulatory Approvals and Acquisitions
- ARS Pharma Expands Neffy Label: ARS Pharmaceuticals received FDA approval to update the Neffy 1mg label, removing age restrictions for individuals weighing over 33 lbs, which is expected to significantly boost market demand and enhance the company's competitive edge in allergy treatment.
- Novo Nordisk Wins Approval for Awiqli: Novo Nordisk's Awiqli (insulin icodec-abae) received FDA approval as the first once-weekly basal insulin, with a U.S. launch planned for 2H 2026, strengthening the company's leadership in diabetes care.
- Biogen Acquires Apellis: Biogen has agreed to acquire Apellis for $41 per share, valuing the deal at approximately $5.6 billion, which is expected to enhance its market share in immunology and rare diseases while driving future revenue growth.
- Takeda's Zasocitinib Clinical Trial Success: Takeda's Zasocitinib showed that about 70% of patients achieved significant skin clearance in Phase 3 trials, with plans to submit a New Drug Application in 2026, further solidifying its position in the dermatology market.
See More
MAIA Biotechnology Reports Significant Progress in THIO-101 Trial
- Survival Milestone: In the THIO-101 trial, eight patients survived beyond two years after receiving Ateganosine followed by Cemiplimab, significantly exceeding standard survival expectations for late-stage non-small cell lung cancer patients, indicating the potential breakthrough nature of this therapy.
- Remarkable Efficacy: One third-line patient achieved 33 months of survival, far surpassing the expected 5.8 months, while four second-line patients lived beyond 30 months, well above the documented 10.5-month survival typically seen with chemotherapy or checkpoint inhibitors alone, highlighting the treatment's effectiveness.
- Trial Design Highlights: THIO-101 is a multicenter, open-label Phase 2 study primarily assessing safety and anti-tumor activity, currently expanding into Part C with plans to enroll 48 additional patients in Asia and Europe, demonstrating an acceptable safety profile in a heavily pre-treated population.
- Broad Market Potential: MAIA aims to develop Ateganosine as a second-line or later treatment for non-small cell lung cancer patients, with the global immunotherapy market projected to exceed $50 billion, positioning Ateganosine as a potential entrant with a novel mechanism and differentiated clinical profile.
See More
MAIA Biotechnology Reports Breakthrough in Lung Cancer Treatment
- Significant Survival Improvement: In the THIO-101 clinical trial, eight non-small cell lung cancer patients achieved overall survival beyond two years, with one patient in third-line therapy surviving 33 months, far exceeding the expected 5.8 months, indicating the potential breakthrough efficacy of this treatment.
- Efficacy Validation: Among 24 patients in second-line therapy, survival exceeded 30 months compared to a standard treatment survival of only 10.5 months, suggesting that this treatment regimen could redefine existing standards of care for heavily pre-treated patients.
- Clinical Trial Expansion: The THIO-101 trial is currently enrolling up to 48 participants in Asia and Europe, further validating the safety and efficacy of this therapy, which is expected to provide new treatment options for heavily pre-treated patients.
- Innovative Mechanism: Ateganosine, as the first telomere-targeting agent, demonstrates unique advantages in treating non-small cell lung cancer by inducing specific immune responses and cancer cell death, potentially paving the way for new cancer treatment strategies.
See More
